Evidence map›Paper›PMID 34458968›Full record

ArticleOphthalmology and therapy2021

Role of Adalimumab Biosimilar in the Treatment of Non-Anterior Uveitis Associated with Behçet's Syndrome.

Jurgen Sota, Stefano Gentileschi, Maria Orsetta Perfetti, Bruno Frediani, Gian Marco Tosi, Luca Cantarini, Claudia Fabiani

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Ophthalmology and therapy, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.7field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 11 citations in OpenAlex.

  1. Adalimumab biosimilars compared to originator: impact on uveitic macular edema.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2026
    Article
  2. Management of Severe Behçet's Disease.Current rheumatology reports · 2026
    Review
  3. Biosimilars in Adult and Pediatric Noninfectious Uveitis.Clinical ophthalmology (Auckland, N.Z.) · 2026
    Review
  4. Article
  5. Article
  6. Pediatric uveitis: Role of the pediatrician.Frontiers in pediatrics · 2022
    Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Jurgen SotaRheumatology Unit, Policlinico "Le Scotte", Department of Medical Sciences, Surgery and Neurosciences, Research Center of Systemic Autoinflammatory Diseases and Behçet's Disease Clinic, University of Siena, Viale Bracci 16, 53100, Siena, Italy.
Stefano GentileschiRheumatology Unit, Policlinico "Le Scotte", Department of Medical Sciences, Surgery and Neurosciences, Research Center of Systemic Autoinflammatory Diseases and Behçet's Disease Clinic, University of Siena, Viale Bracci 16, 53100, Siena, Italy.
Maria Orsetta PerfettiOphthalmology Unit, Department of Medicine, Surgery and Neuroscience, University of Siena, Siena, Italy.
Bruno FredianiRheumatology Unit, Policlinico "Le Scotte", Department of Medical Sciences, Surgery and Neurosciences, Research Center of Systemic Autoinflammatory Diseases and Behçet's Disease Clinic, University of Siena, Viale Bracci 16, 53100, Siena, Italy.
Gian Marco TosiOphthalmology Unit, Department of Medicine, Surgery and Neuroscience, University of Siena, Siena, Italy.
Luca CantariniRheumatology Unit, Policlinico "Le Scotte", Department of Medical Sciences, Surgery and Neurosciences, Research Center of Systemic Autoinflammatory Diseases and Behçet's Disease Clinic, University of Siena, Viale Bracci 16, 53100, Siena, Italy. cantariniluca@hotmail.com.ORCID http://orcid.org/0000-0002-7352-1275
Claudia FabianiOphthalmology Unit, Department of Medicine, Surgery and Neuroscience, University of Siena, Siena, Italy.
University of Siena · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionTo evaluate the efficacy of SB5, an adalimumab biosimilar, in the management of Behçet's syndrome (BS)-related uveitis.

methodsData from eight BS patients (16 eyes) with active non-anterior uveitis and/or systemic uncontrolled disease or performing non-medical switch to SB5 were retrospectively collected and analyzed.

resultsComplete control of uveitis was observed in all 16 eyes without relapses during follow-up. The number of relapses 12 months prior to SB5 initiation and at last follow-up was 100 and 0 per 100 patients/year, respectively (p = 0.010). At baseline, four eyes had active retinal vasculitis, whereas at 3 months and at last follow-up, retinal vasculitis had resolved in all of them (p = 0.018). Median visual acuity did not vary significantly between baseline and last follow-up visit (p = 0.109). No ocular complications emerged during treatment.

conclusionsSB5 is effective in the treatment of BS-related non-anterior uveitis. It reduces uveitis relapses and controls retinal vasculitis while allowing preservation of visual acuity.

Indexed as

AdalimumabBehçet’s syndromeBiosimilarRetinal vasculitisUveitis

Identifiers

PMID34458968
PMCPMC8589899
OpenAlexW3198275052

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.